Physician profile
Julia E Turney
NPI 1467170399
$1,824.90
in general payments reported to CMS, 2019-2025
24 companies · $716 in 2025
The $716 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $471 · 2023: $618 · 2024: $20.39 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.33 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $221.50 | 2022-2025 | Fruzaqla |
| Genentech USA, INC. | $178.68 | 2023-2025 | Tecentriq, Itovebi |
| Merck Sharp & Dohme LLC | $136.33 | 2022-2024 | Lynparza |
| Ipsen Biopharmaceuticals, INC | $125.70 | 2025 | Onivyde |
| Emd Serono, INC. | $125.00 | 2023 | Tepmetko |
| E.R. Squibb & Sons, L.L.C. | $124.81 | 2023 | Opdivo |
| Rigel Pharmaceuticals, INC. | $121.66 | 2022 | |
| Tactile Systems Technology INC | $118.18 | 2023 | Entre Plus, Flexitouch Plus |
| Pharmacosmos Therapeutics INC. | $90.76 | 2022 | |
| Deciphera Pharmaceuticals INC. | $77.22 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $72.93 | 2025 | Lynozyfic |
| Abbvie INC. | $54.47 | 2025 | |
| Eisai INC. | $54.04 | 2025 | |
| Pfizer INC. | $47.57 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.53 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $38.38 | 2025 | Padcev |
| Amgen INC. | $28.14 | 2025 | Imdelltra (Amg757) |
| Array Biopharma INC | $26.11 | 2025 | Mektovi, Tukysa, Braftovi |
| Novartis Pharmaceuticals Corporation | $26.06 | 2025 | |
| Sobi, INC | $25.78 | 2025 | |
| Incyte Corporation | $25.24 | 2025 | Jakafi |
| Genzyme Corporation | $22.64 | 2025 | |
| Puma Biotechnology, INC. | $21.72 | 2025 | |
| Servier Pharmaceuticals LLC | $17.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Turney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.